title: Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction.
abstract: Objective To assess whether adjuvant chemotherapy with bevacizumab intraperitoneal (i.p.) is better than adjuvant chemotherapy with bevacizumab intravenous (i.v.) or adjuvant chemotherapy only for patients with advanced ovarian cancer after cytoreduction. Selected patients with advanced ovarian cancer after cytoreduction were divided into three groups depend on their will: adjuvant chemotherapy only; adjuvant chemotherapy combined with bevacizumab intravenous (i.v.); adjuvant chemotherapy combined with bevacizumab intraperitoneal (i.p.). Patients in three groups were given 4-6 cycles of treatment and followed up for 3 years. posttreatment outcome, longterm survival and side effects were prospectively recorded and analyzed. Disease control rate (DCR) of three groups are 73.3%, 90.0%, 93.3% respectively (P<0.05). Remission rate (RR) and DCR of patients with bevacizumab intraperitoneal (i.p.) are better than that of patients with bevacizumab intravenous (i.v.) (P<0.05). The mean progression free survival (PFS) of patients with bevacizumab intraperitoneal (i.p.) (15.34 months) was longer than patients with bevacizumab intravenous (i.v.) (13.19 months), and both of two were longer than that of patients with adjuvant chemotherapy only (9.60 months) (χ2=52.11, P<0.001). The mean overall survival (OS) of patients with bevacizumab intraperitoneal (i.p.) (17.32 months) is longer than that of patients with adjuvant chemotherapy only (13.55 months) and patients with bevacizumab intravenous (i.v.) (15.17 months) (χ2=75.01, P<0.001). Incidence of hypertension and arrhythmia of groups with bevacizumab are higher than that of patients with adjuvant chemotherapy only (P<0.05). Standard chemotherapy combined with bevacizumab is reliable, safe and feasible for advanced ovarian cancer after cytoreduction without severe adverse effects. Bevacizumab intraperitoneal perfusion is better than that intravenous drip.
authors.forename: F
authors.initials: F
authors.lastname: DU
authors.forename: P
authors.initials: P
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: Z
authors.initials: Z
authors.lastname: Gong
authors.forename: C
authors.initials: C
authors.lastname: Chi
authors.forename: B
authors.initials: B
authors.lastname: Hu
authors.forename: H
authors.initials: H
authors.lastname: Chu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000068258:Bevacizumab / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D065426:Cytoreduction Surgical Procedures; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D000068258:Bevacizumab
keywords: bevacizumab; ovarian cancer adjuvant chemotherapy.